Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period.
Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.
Investors should closely monitor whether the revenue gap between the two companies continues to widen in upcoming quarters or eventually begins to narrow.
Johnson & Johnson (NYSE:JNJ) primarily generates revenue by developing and selling pharmaceutical and medical technology products globally.
It recently entered a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, and it received U.S. Food and Drug Administration approval for a new targeted cancer therapy.
Pfizer (NYSE:PFE) primarily generates revenue by developing, manufacturing, and commercializing prescription medicines and vaccines for individuals worldwide.
It recently announced a $1.5 billion funding agreement with Blackstone Life Sciences, and it secured expanded regulatory approval from the U.S. Food and Drug Administration for a cancer treatment regimen.
Revenue here refers to the data provider's standardized income-statement revenue line item, and it shows the total money a business brings in from sales before deducting any operating costs.
Johnson & Johnson vs. Pfizer Revenue over the last 8 quarters.
| Calendar quarter | Johnson & Johnson Revenue | Pfizer Revenue |
|---|---|---|
| Q4 2024 | $22.5 billion (quarter ended Dec. 29, 2024) | $17.8 billion (quarter ended Dec. 31, 2024) |
| Q1 2025 | $21.9 billion (quarter ended March 30, 2025) | $13.7 billion (quarter ended March 30, 2025) |
| Q2 2025 | $23.7 billion (quarter ended June 29, 2025) | $14.7 billion (quarter ended June 29, 2025) |
| Q3 2025 | $24.0 billion (quarter ended Sept. 28, 2025) | $16.7 billion (quarter ended Sept. 28, 2025) |
| Q4 2025 | $24.6 billion (quarter ended Dec. 28, 2025) | $17.6 billion (quarter ended Dec. 31, 2025) |
| Q1 2026 | $24.1 billion (quarter ended March 29, 2026) | $14.4 billion (quarter ended March 29, 2026) |
| Q2 2026 | $25.3 billion (quarter ended June 28, 2026) | $15.0 billion (quarter ended June 28, 2026) |
| Q3 2026 | $25.4 billion (quarter ended Sept. 27, 2026) | $16.6 billion (quarter ended Sept. 27, 2026) |
First off, don't be concerned about the drops in revenue you see in the chart for both companies as you read left to right. That reflects the seasonality of the businesses, which often can be traced back to doctors and patients loading up on prescriptions toward the end of a calendar year, when many patients have met their health insurance deductibles.
While ideally, a quarterly revenue chart would show rising bars from left to right, this seasonality means a better evaluation would be to compare each quarter to its prior-year quarter. For instance, JNJ's third quarter of 2026 saw positive gains over the third quarter of 2025. Yet Pfizer's sales actually show a slight dip in Q3 2026 compared to the same period in 2025. That's a red flag for investors to pay attention to.
We also do see less fluctuation from JNJ, in part because the business has 28 products and platforms that each generate more than $1 billion in annual sales. Pfizer, meanwhile, is trying to recover from a post-COVID-19 letdown, with fewer people getting the COVID vaccine each year as we get further from the pandemic.
Data source: Financial Modeling Prep. Data as of Nov. 17, 2026.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.